Formononetin, recognized for its extensive pharmacological effects in neurological disorders, organ damage, and cancer (Min Jin et al., 2025; M. Jin et al., 2025), has been shown to ameliorate high glucose-induced endothelial dysfunction and inhibit the JAK/STAT signaling pathway (Zhou et al., 2019). This evidence concerns the gene SOAT1 and endothelial dysfunction.